Dennis Lanfear - Coherus BioSciences Chairman, CEO and Pres
| CHRS Stock | USD 1.39 0.03 2.11% |
Chairman
Mr. Dennis M. Lanfear is Chairman of the Board, President, Chief Executive Officer of the Coherus BioSciences, Inc. He is our cofounder and has served as our President and Chief Executive Officer and as a member of our Board of Directors since our inception in September 2010. Mr. Lanfear previously was President of InteKrin Therapeutics Inc., a biopharmaceutical company, from 2005 to May 2010. Prior to that, Mr. Lanfear served in various senior leadership roles at Amgen Inc., a biopharmaceutical company from 1986 to 1999. While at Amgen, Mr. Lanfear had key leadership positions in the Process Development department, which under his management became an area of key strategic advantage for Amgen. Mr. Lanfear has also held senior leadership roles in several product development programs including those for growth factors, somatotrophins and neurotrophins and directed efforts from preclinical studies to Phase 3 clinical trials at Amgen since 2016.
| Age | 70 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Address | 333 Twin Dolphin Drive, Redwood City, CA, United States, 94065 |
| Phone | 650 649 3530 |
| Web | https://www.coherus.com |
Dennis Lanfear Latest Insider Activity
Tracking and analyzing the buying and selling activities of Dennis Lanfear against Coherus BioSciences stock is an integral part of due diligence when investing in Coherus BioSciences. Dennis Lanfear insider activity provides valuable insight into whether Coherus BioSciences is net buyers or sellers over its current business cycle. Note, Coherus BioSciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Coherus BioSciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Dennis Lanfear over a week ago Acquisition by Dennis Lanfear of 575000 shares of Coherus BioSciences at 1.47 subject to Rule 16b-3 |
Coherus BioSciences Management Efficiency
The company has return on total asset (ROA) of (0.1403) % which means that it has lost $0.1403 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (16.5706) %, meaning that it created substantial loss on money invested by shareholders. Coherus BioSciences' management efficiency ratios could be used to measure how well Coherus BioSciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 1.97 in 2025, whereas Return On Tangible Assets are likely to drop (0.40) in 2025. At this time, Coherus BioSciences' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 86.1 M in 2025, whereas Total Current Assets are likely to drop slightly above 311.1 M in 2025.Similar Executives
| Found 1 records | CHAIRMAN Age | ||
| Sean DPHIL | CytomX Therapeutics | 58 | |
Management Performance
| Return On Equity | -16.57 | ||||
| Return On Asset | -0.14 |
Coherus BioSciences Leadership Team
Elected by the shareholders, the Coherus BioSciences' board of directors comprises two types of representatives: Coherus BioSciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Coherus. The board's role is to monitor Coherus BioSciences' management team and ensure that shareholders' interests are well served. Coherus BioSciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Coherus BioSciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Vladimir Vexler, Chief Scientific Officer | ||
| Bryan Mcmichael, Principal Accounting | ||
| Dennis Lanfear, Chairman, CEO and Pres | ||
| Michael Chen, Senior Trade | ||
| Theresa Lavallee, Chief Board | ||
| MRCP MD, Chief Officer | ||
| Rebecca Sunshine, Chief Officer | ||
| Scott Saywell, Executive Development | ||
| Jodi Sievers, Vice Communications | ||
| Karen Kotz, Ex Accounts | ||
| Jami Taylor, Vice Relations | ||
| Christopher Slavinsky, Chief Officer | ||
| Cheston Turbyfill, Vice Communications | ||
| Andy Rittenberg, Executive Counsel | ||
| McDavid Stilwell, Chief Officer | ||
| Paul Reider, Chief Officer | ||
| Richard Hameister, Chief Officer |
Coherus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Coherus BioSciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -16.57 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 332.33 M | ||||
| Shares Outstanding | 115.21 M | ||||
| Shares Owned By Insiders | 1.30 % | ||||
| Shares Owned By Institutions | 69.78 % | ||||
| Number Of Shares Shorted | 30.72 M | ||||
| Price To Earning | 4.22 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.